Oral Wegovy proves mettle, now next generation should complement
04/11/26 -"The weight-loss Wegovy pill drove the Q3 beat, while most key drugs suffered from pricing and competitive pressures. With the previous outlook being overly conservative, the management upgraded its ..."
Pages
73
Language
English
Published on
04/11/26
You may also be interested by these reports :
12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...